Infection and atherosclerosis: Mechanisms involving Chlamydia pneumoniae in cardiovascular disease

Gerald I. Byrne; Scot P. Ouellette; Robert J. Belland

doi:10.1016/S0531-5131(03)01862-4

Infection and atherosclerosis: Mechanisms involving Chlamydia pneumoniae in cardiovascular disease

Gerald I. Byrne, Scot P. Ouellette, Robert J. Belland

Pathology & Microbiology

Research output: Contribution to journal › Article › peer-review

Abstract

The intracellular bacterium Chlamydia pneumoniae is present in atherosclerotic plaques and may contribute to progression and vulnerability of lesions. Results from animal models support a causal role for C. pneumoniae in atherosclerosis and virulence attributes ascribed to this organism are consistent with this view. Results from recent antibiotic treatment trials have not proven effective, but additional work is needed to define reasons for these failures.

Original language	English (US)
Pages (from-to)	426-429
Number of pages	4
Journal	International Congress Series
Volume	1262
Issue number	C
DOIs	https://doi.org/10.1016/S0531-5131(03)01862-4
State	Published - May 1 2004

Keywords

Atherosclerosis
Chlamydia pneumoniae
Chronic infection
GroEL
Pathogenesis

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0531-5131(03)01862-4

Fingerprint Dive into the research topics of 'Infection and atherosclerosis: Mechanisms involving Chlamydia pneumoniae in cardiovascular disease'. Together they form a unique fingerprint.

Cite this

@article{66d80641ce734f8b81426c422cb3920f,

title = "Infection and atherosclerosis: Mechanisms involving Chlamydia pneumoniae in cardiovascular disease",

abstract = "The intracellular bacterium Chlamydia pneumoniae is present in atherosclerotic plaques and may contribute to progression and vulnerability of lesions. Results from animal models support a causal role for C. pneumoniae in atherosclerosis and virulence attributes ascribed to this organism are consistent with this view. Results from recent antibiotic treatment trials have not proven effective, but additional work is needed to define reasons for these failures.",

keywords = "Atherosclerosis, Chlamydia pneumoniae, Chronic infection, GroEL, Pathogenesis",

author = "Byrne, {Gerald I.} and Ouellette, {Scot P.} and Belland, {Robert J.}",

year = "2004",

month = may,

day = "1",

doi = "10.1016/S0531-5131(03)01862-4",

language = "English (US)",

volume = "1262",

pages = "426--429",

journal = "International Congress Series",

issn = "0531-5131",

publisher = "Elsevier BV",

number = "C",

}

TY - JOUR

T1 - Infection and atherosclerosis

T2 - Mechanisms involving Chlamydia pneumoniae in cardiovascular disease

AU - Byrne, Gerald I.

AU - Ouellette, Scot P.

AU - Belland, Robert J.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - The intracellular bacterium Chlamydia pneumoniae is present in atherosclerotic plaques and may contribute to progression and vulnerability of lesions. Results from animal models support a causal role for C. pneumoniae in atherosclerosis and virulence attributes ascribed to this organism are consistent with this view. Results from recent antibiotic treatment trials have not proven effective, but additional work is needed to define reasons for these failures.

AB - The intracellular bacterium Chlamydia pneumoniae is present in atherosclerotic plaques and may contribute to progression and vulnerability of lesions. Results from animal models support a causal role for C. pneumoniae in atherosclerosis and virulence attributes ascribed to this organism are consistent with this view. Results from recent antibiotic treatment trials have not proven effective, but additional work is needed to define reasons for these failures.

KW - Atherosclerosis

KW - Chlamydia pneumoniae

KW - Chronic infection

KW - GroEL

KW - Pathogenesis

UR - http://www.scopus.com/inward/record.url?scp=85023131469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023131469&partnerID=8YFLogxK

U2 - 10.1016/S0531-5131(03)01862-4

DO - 10.1016/S0531-5131(03)01862-4

M3 - Article

AN - SCOPUS:85023131469

VL - 1262

SP - 426

EP - 429

JO - International Congress Series

JF - International Congress Series

SN - 0531-5131

IS - C

ER -